Polyphor N Aktie

ISIN: CH0106213793 Land: Sonstiges
Branche: Sonstiges
Sektor: Sonstiges
boerse.de Prädikat:
aktueller Kurs:
6,81 EUR
Veränderung:
0,03 EUR
Veränderung in %:
0,44 %
weitere Analysen einblenden

EQS-Adhoc: Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Dienstag, 05.01.21 07:30
Newsbild
Bildquelle: fotolia.com

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Conference
Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

05-Jan-2021 / 07:30 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 KR
The issuer is solely responsible for the content of this announcement.


Allschwil, Switzerland, January 5, 2021

Polyphor to take part in panel discussion on novel oncology targets at the LifeSci Partners 10th Annual Healthcare Corporate Access Event

Polyphor AG (SIX: POLN) announced today that Gökhan Batur, Chief Executive Officer, will take part in a panel discussion at the LifeSci Partners 10th Annual Healthcare Corporate Access Event on Thursday, January 7 from 8:00AM Eastern Standard Time.

The panel is entitled "Separating the Wheat from the Chaff: Most Promising Novel Oncology Targets in Development". Investors can pre-register for the event here.

Polyphor is currently conducting the Phase III FORTRESS trial with balixafortide, a potent and selective CXCR4 antagonist, in patients with HER2 negative, locally recurrent or metastatic breast cancer. Data on the key primary endpoint of FORTRESS, progression free survival (PFS) in the overall population, is planned for Q4 2021. An analysis of the objective response rate (ORR) in eligible patients in third and later lines of chemotherapy is planned for Q2 2021.

For further information please contact:

For Investors:

Hernan Levett
Chief Financial Officer
Polyphor Ltd.
+41 61 567 16 00
IR@polyphor.com
Mary-Ann Chang
LifeSci Advisors
Tel: +44 7483 284 853
mchang@lifesciadvisors.com
 

For Media:
Bernhard Schmid
LifeSci Advisors
+41 44 447 12 21
bschmid@lifesciadvisors.com

About Polyphor
Polyphor is a research-driven clinical-stage, Swiss biopharmaceutical company committed to discovering and developing first-in-class molecules in oncology and antimicrobial resistance leveraging the company's leading macrocyclic peptide technology platform. Polyphor is advancing balixafortide (POL6326) in a Phase III trial in combination with eribulin in patients with advanced breast cancer and exploring its potential in other cancer indications. In addition, it has discovered and is developing the Outer Membrane Protein Targeting Antibiotics (OMPTA). OMPTA are potentially the first new class of antibiotics in clinical development in the last 50 years against Gram-negative bacteria. The company's lead OMPTA program is an inhaled formulation of murepavadin for the treatment of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Polyphor is based in Allschwil near Basel and is listed on the SIX Swiss Exchange (SIX: POLN). For more information, please visit www.polyphor.com.

Disclaimer
This press release contains forward-looking statements which are based on current assumptions and forecasts of the Polyphor management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular Polyphor's results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. Polyphor disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.



End of ad hoc announcement
Language: English
Company: Polyphor AG
Hegenheimermattweg 125
4123 Allschwil
Switzerland
Phone: +41 61 567 1600
Fax: +41 61 567 1601
E-mail: info@polyphor.com
Internet: www.polyphor.com
ISIN: CH0106213793
Valor: POLN
Listed: SIX Swiss Exchange
EQS News ID: 1158405

 
End of Announcement EQS Group News Service

1158405  05-Jan-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1158405&application_name=news&site_id=boerse_de



Quelle: DGAP




Heute im Fokus

2021: Diese Aktien sollten Sie im Depot haben!
2021: Welche Aktien sollten Sie im Depot haben?
2021: Welche Aktien sollten Sie im Depot haben?
Das turbulente Börsenjahr 2020 ist Geschichte! Doch welche Aktien sollten Sie 2021 im Depot haben?...

News und Analysen

EQS-Adhoc: Polyphor to present full-year 2020 financial results on March 5

EQS Group-Ad-hoc: Polyphor AG / Key word(s): Annual Results Polyphor to present full-year 2020 financial results on March 5 26-Feb-2021 / 07:30 CET/CEST Release of an ad hoc announcement ...weiterlesen

Seite: 1 | 2 | ►

Polyphor N Aktie Chart Profichart

Chart
© 1994-2021 by boerse.de - Quelle für Kurse und Daten: ARIVA.DE AG - boerse.de übernimmt keine Gewähr